Capricor Therapeutics Inc., of Los Angeles, said it acquired patent rights from Minneapolis-based Medtronic Inc. relating to the formulation and pump delivery of natriuretic peptides, such as cenderitide, a natriuretic peptide for the treatment of post-acute heart failure.